Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.

Autor: Campbell A; Department of Haematology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia., Teh B; National Centre for Infections in Cancer and Department of Infectious Diseases, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia., Mulligan S; Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia., Ross DM; SA Pathology and Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Department of Haematology, Flinders University and Medical Centre, Adelaide, South Australia, Australia., Weinkove R; Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand., Gilroy N; Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, New South Wales, Australia., Gangatharan S; Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.; University of Western Australia, Perth, Western Australia, Australia., Prince HM; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Department of Haematology, Epworth Healthcare, Melbourne, Victoria, Australia.; University of Melbourne, Melbourne, Victoria, Australia., Szer J; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.; University of Melbourne, Melbourne, Victoria, Australia., Trotman J; Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.; Department of Haematology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Lane S; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.; School of Medicine, University of Queensland, Brisbane, Queensland, Australia.; Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia., Dickinson M; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.; University of Melbourne, Melbourne, Victoria, Australia., Quach H; University of Melbourne, Melbourne, Victoria, Australia.; Department of Haematology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia., Enjeti AK; Department of Haematology, Calvary Mater Hospital, Newcastle, New South Wales, Australia.; New South Wales Health Pathology, John Hunter Hospital, Newcastle, New South Wales, Australia.; University of Newcastle, Newcastle, New South Wales, Australia., Ku M; University of Melbourne, Melbourne, Victoria, Australia.; Department of Haematology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia., Gregory G; Department of Haematology, Monash Health, Melbourne, Victoria, Australia., Hapgood G; Department of Haematology, Princess Alexandra Hospital, Melbourne, Victoria, Australia., Ho PJ; Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.; Department of Haematology, Royal Prince Alfred Hospital, Melbourne, Victoria, Australia., Cochrane T; Department of Haematology, Gold Coast University Hospital, Gold Coast, Queensland, Australia., Cheah C; University of Western Australia, Perth, Western Australia, Australia.; Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.; Department of Haematology, Pathwest Laboratory Medicine, Perth, Western Australia, Australia., Greenwood M; Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia., Latimer M; Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia., Berkahn L; Department of Haematology, The Auckland City Hospital, Auckland, New Zealand.; University of Auckland, Auckland, New Zealand., Wight J; Townsville University Hospital, Townsville, Queensland, Australia., Armytage T; Gosford Hospital, Gosford, New South Wales, Australia., Diamond P; Leukaemia Foundation, Sydney, New South Wales, Australia., Tam CS; Department of Haematology, Alfred Hospital, Melbourne, Victoria, Australia.; Central Clinical School, Monash University, Melbourne, Victoria, Australia.; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia., Hamad N; Department of Haematology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; School of Medicine, University of Notre Dame Australia, Sydney, New South Wales, Australia.
Jazyk: angličtina
Zdroj: Internal medicine journal [Intern Med J] 2024 Feb; Vol. 54 (2), pp. 328-336. Date of Electronic Publication: 2023 Dec 25.
DOI: 10.1111/imj.16303
Abstrakt: Despite widespread vaccination rates, we are living with high transmission rates of SARS-CoV-2. Although overall hospitalisation rates are falling, the risk of serious infection remains high for patients who are immunocompromised because of haematological malignancies. In light of the ongoing pandemic and the development of multiple agents for treatment, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 management in patients with haematological disorders. It is our recommendation that both patients with haematological malignancies and treating specialists be educated regarding the preventive and treatment options available and that patients continue to receive adequate vaccinations, keeping in mind the suboptimal vaccine responses that occur in haematology patients, in particular, those with B-cell malignancies and on B-cell-targeting or depleting therapy. Patients with haematological malignancies should receive treatment for COVID-19 in accordance with the severity of their symptoms, but even mild infections should prompt early treatment with antiviral agents. The issue of de-isolation following COVID-19 infection and optimal time to treatment for haematological malignancies is discussed but remains an area with evolving data. This position statement is to be used in conjunction with advice from infectious disease, respiratory and intensive care specialists, and current guidelines from the National COVID-19 Clinical Evidence Taskforce and the New Zealand Ministry of Health and Cancer Agency Te Aho o Te Kahu COVID-19 Guidelines.
(© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.)
Databáze: MEDLINE
Externí odkaz: